A Single-arm, Open-label Phase I Clinical Study to Evaluate ICG318 CAR-T in Adults With Refractory Inflammatory Bowel Disease
Latest Information Update: 29 Apr 2026
At a glance
- Drugs BCMA CD19 cCAR T-cell therapy-iCell Gene Therapeutics (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- Sponsors iCell Gene Therapeutics
Most Recent Events
- 29 Apr 2026 New trial record